Amgen shares fall as 2019 guidance disappoints

30 January 2019
amgen-logo-big

Shares of US biotech major Amgen (Nasdaq: AMGN) dipped 2.43% to $187.45 in after-hours trading yesterday, when the company released its financial results for 2018.

For the full year, total revenues increased 4% to $23.7 billion, with 3% product sales growth. Generally accepted accounting principles (GAAP) earnings per share (EPS) increased to $3.01 in the fourth quarter and to $12.62 for the full year driven by higher total revenues, a lower tax rate as the prior year was impacted by US tax reform and lower weighted-average shares outstanding.

For the fourth quarter, total revenues increased 7% to $6.2 billion versus $5.84 billion, forecast by Refinitiv. For the fourth quarter, GAAP operating income increased 6% to $2.4 billion and GAAP operating margin decreased 0.6 percentage points to 39.7 %. For the full year, GAAP operating income increased 3% to $10.3 billion and GAAP operating margin decreased 0.3 percentage points to 45.5%. Earnings per share were $3.42, versus $3.27, forecast by Refinitiv US biotech major Amgen (Nasdaq:

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Company News Directory

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology